血管生成因子、程序性死亡受体1及其配体在肺腺癌中的表达及与患者预后的关系  

Expression of angiogenic factors,programmed cell death 1 and its ligand in lung adenocarcinoma and their relationship with prognosis

作　　者：高翔[1] 庞琼[1] 王莹 GAO Xiang;PANG Qiong;WANG Ying(Department of Oncology,Hanzhong Central Hospital,Hanzhong 723000,Shaanxi,China)

机构地区：[1]汉中市中心医院肿瘤内科,陕西汉中723000

出　　处：《癌症进展》2022年第8期805-808,812,共5页Oncology Progress

摘　　要：目的探讨血管内皮生长因子A(VEGFA)、血管内皮生长因子受体2(VEGFR2)、程序性死亡受体1(PD-1)、程序性死亡受体配体1(PD-L1)在肺腺癌中的表达及与患者预后的关系。方法选取126例肺腺癌患者和126例健康体检者分别作为研究组和对照组,采用酶联免疫吸附试验检测两组受试者血清VEGFA、VEGFR2、PD-1及PD-L1水平。采用免疫组化法检测肺腺癌患者肺腺癌组织中VEGFA、VEGFR2、PD-1及PD-L1蛋白的阳性表达率,并分析其与患者临床特征的关系。随访1年,比较不同预后情况肺腺癌患者血清VEGFA、VEGFR2、PD-1及PD-L1水平。绘制受试者工作特征(ROC)曲线,计算曲线下面积(AUC),评估VEGFA、VEGFR2、PD-1及PD-L1对肺腺癌患者预后的预测价值。结果研究组患者血清VEGFA、VEGFR2、PD-1及PD-L1水平均明显高于对照组受试者(P﹤0.01),肺腺癌患者VEGFA、VEGFR2、PD-1及PD-L1蛋白阳性表达率分别为43.65%、42.86%、46.83%、42.86%。存在淋巴结转移、临床分期为Ⅲ期肺腺癌患者肺腺癌组织中VEGFA、VEGFR2、PD-1及PD-L1蛋白阳性表达率均高于无淋巴结转移、临床分期为Ⅰ~Ⅱ期的患者(P﹤0.05)。随访1年,126例肺腺癌患者生存94例,死亡32例,死亡患者血清VEGFA、VEGFR2、PD-1及PD-L1水平均明显高于生存患者(P﹤0.01)。VEGFA、VEGFR2、PD-1及PD-L1预测肺腺癌患者预后的AUC分别为0.823、0.836、0.860、0.833,均较高。结论肺腺癌患者肺腺癌组织中VEGFA、VEGFR2、PD-1及PD-L1表达明显上调,且对患者预后有一定的评估价值。Objective To investigate the expression of vascular endothelial growth factor A(VEGFA),vascular endothelial growth factor receptor 2(VEGFR2),programmed cell death 1(PD-1)and programmed cell death 1 ligand 1(PD-L1)in lung adenocarcinoma and their relationship with prognosis.Method A total of 126 patients with lung adenocarcinoma and 126 healthy subjects were selected as research group and control group,and the serum VEGFA,VEGFR2,PD-1,and PD-L1 levels of the two groups were detected by the enzyme-linked immunosorbent assay.The immunohistochemical method was used to detect the positive rates of VEGFA,VEGFR2,PD-1,and PD-L1 proteins in lung adenocarcinoma tissues from patients with lung adenocarcinoma,and the relationship between the biomarkers and the clinical features of patients were analyzed.After 1-year follow-up,the serum levels of VEGFA,VEGFR2,PD-1,and PD-L1 in patients with lung adenocarcinoma of different prognoses were compared.The receiver operating characteristic(ROC)curve was drawn to calculate the area under the curve(AUC),and the prognostic value of VEGFA,VEGFR2,PD-1,and PD-L1 in patients with lung adenocarcinoma was also assessed.Result The serum levels of VEGFA,VEGFR2,PD-1,and PD-L1 in the research group were significantly higher than those in the control group(P<0.01).The positive rates of VEGFA,VEGFR2,PD-1,and PD-L1 in patients with lung adenocarcinoma were 43.65%,42.86%,46.83%,and 42.86%respectively.The positive rates of VEGFA,VEGFR2,PD-1,and PD-L1 in lung adenocarcinoma tissues of patients with lymph node metastasis and clinical stage III lung adenocarcinoma were all higher than those of patients without lymph node metastasis and clinical stage I to II(P<0.05).After 1-year follow-up among 126 patients with lung adenocarcinoma,94 cases survived,32 cases died,and the serum levels of VEGFA,VEGFR2,PD-1 and PD-L1 in the dead patients were significantly higher than those in the surviving patients(P<0.01).The prognostic AUC of VEGFA,VEGFR2,PD-1,and PD-L1 in patients with lung adenocarcinoma were 0.823,0.

关 键 词：肺腺癌 血管内皮生长因子 程序性死亡受体1 程序性死亡受体配体1 

分 类 号：R734.2[医药卫生—肿瘤]